更新版 1-J&J 将以 20 亿美元收购癌症疗法开发商 Ambrx

Reuters01-08

((自动化翻译由路透提供，请见免责声明 )) (增加交易细节，背景贯穿始终)

路透1月8日 - 强生周一表示，已同意以 20 亿美元收购药物开发商 Ambrx Biopharma ，以获得其癌症靶向疗法产品组合。

J&J将以每股28美元的价格收购Ambrx，与该股上次收盘价相比溢价约105%。

Ambrx公司正在开发的疗法属于抗体药物共轭物类药物$(ADC)$，研究人员称其为 "制导导弹"，可靶向癌细胞，并最大限度地减少对健康组织的损害。

J&J 的收购是该领域宣布的最新交易。11月，艾伯维表示 (link)，将以101亿美元现金收购ADC开发商ImmunoGen 。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2401930011?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-01-08 20:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2401930011","market":"us","top_or_hot":-1,"title":"更新版 1-J&J 将以 20 亿美元收购癌症疗法开发商 Ambrx","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 )) (增加交易细节，背景贯穿始终)</p><p>    路透1月8日 - <a href=\"https://laohu8.com/S/JNJ\">强生</a>  周一表示，已同意以 20 亿美元收购药物开发商 Ambrx Biopharma   ，以获得其癌症靶向疗法产品组合。 </p><p>J&amp;J将以每股28美元的价格收购Ambrx，与该股上次收盘价相比溢价约105%。 </p><p>Ambrx公司正在开发的疗法属于抗体药物共轭物类药物<a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>，研究人员称其为 \"制导导弹\"，可靶向癌细胞，并最大限度地减少对健康组织的损害。 </p><p>J&amp;J 的收购是该领域宣布的最新交易。11月，艾伯维  表示 (link)，将以101亿美元现金收购ADC开发商<a href=\"https://laohu8.com/S/IMGN\">ImmunoGen</a>  。 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>更新版 1-J&J 将以 20 亿美元收购癌症疗法开发商 Ambrx</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n更新版 1-J&J 将以 20 亿美元收购癌症疗法开发商 Ambrx\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-08 20:44 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 )) (增加交易细节，背景贯穿始终)    路透1月8日 - 强生  周一表示，已同意以 20 亿美元收购药物开发商 Ambrx Biopharma   ，以获得其癌症靶向疗法产品组合。 J&J将以每股28美元的价格收购Ambrx，与该股上次收盘价相比溢价约105%。 Ambrx公司正在开发的疗法属于抗体药物共轭物类药物$(ADC)$，研究人员称其为 \"制导...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2602419157.SGD","symbol_name":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2401930011","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2401930011","pubTimestamp":1704717884,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 )) (增加交易细节，背景贯穿始终)    路透1月8日 - 强生  周一表示，已同意以 20 亿美元收购药物开发商 Ambrx Biopharma   ，以获得其癌症靶向疗法产品组合。 J&J将以每股28美元的价格收购Ambrx，与该股上次收盘价相比溢价约105%。 Ambrx公司正在开发的疗法属于抗体药物共轭物类药物(ADC)，研究人员称其为 \"制导导弹\"，可靶向癌细胞，并最大限度地减少对健康组织的损害。 J&J 的收购是该领域宣布的最新交易。11月，艾伯维  表示 (link)，将以101亿美元现金收购ADC开发商ImmunoGen  。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","BK4581":"高盛持仓","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4504":"桥水持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","AMAM":"Ambrx Biopharma Inc","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","BK4539":"次新股","BK4231":"零售房地产信托","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4592":"伊斯兰概念","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4534":"瑞士信贷持仓","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999002232.USD":"Allianz Global High Payout USD","BK4007":"制药","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","BK4559":"巴菲特持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1032466523.USD":"高盛全球多资产收益组合Acc","JNJ":"强生","BK4588":"碎股","BK4550":"红杉资本持仓","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0122379950.USD":"贝莱德世界健康科学A2","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","ADC":"艾格里房产","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD"},"translate_title":"Updated 1-J&J to buy cancer therapy developer Ambrx for $2 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADC":1,"AMAM":0.9,"JNJ":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 )) (增加交易细节，背景贯穿始终)    路透1月8日 - 强生  周一表示，已同意以 20 亿美元收购药物开发商 Ambrx Biopharma   ，以获得其癌症靶向疗法产品组合。 J&J将以每股28美元的价格收购Ambrx，与该股上次收盘价相比溢价约105%。 Ambrx公司正在开发的疗法属于抗体药物共轭物类药物$(ADC)$，研究人员称其为 \"制导导弹\"，可靶向癌细胞，并最大限度地减少对健康组织的损害。 J&J 的收购是该领域宣布的最新交易。11月，艾伯维  表示 (link)，将以101亿美元现金收购ADC开发商ImmunoGen  。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2401930011"}